Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-000373-21
    Sponsor's Protocol Code Number:IRX-22015A
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2016-08-17
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2016-000373-21
    A.3Full title of the trial
    A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy with the IRX-2 Regimen in Patients with Newly Diagnosed Stage II, III or IVA Squamous Cell Carcinoma of the Oral Cavity
    Estudio de Fase 2, aleatorizado, del tratamiento neoadyuvante y adyuvante con el régimen IRX-2 en pacientes con diagnóstico reciente de carcinoma de células escamosas de la cavidad oral, estadio II, III o IVA
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Randomized Phase-2 Trial to Evaluate the Effects of the IRX-2 Regimen before Surgery and after Chemotherapy or Radiation in Newly Diagnosed Patients with Stage II, III or IVA Squamous Cell Cancer of the Oral Cavity
    Estudio de Fase 2 para evaluar los efectos del régimen IRX-2 antes de la cirugía y después de la quimioterapia o radiación en pacientes con diagnóstico reciente de carcinoma de células escamosas de la cavidad oral, estadio II, III o IVA
    A.4.1Sponsor's protocol code numberIRX-22015A
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT02609386
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorIRX Therapeutics, Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportIRX Therapeutics, Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationPivotal, S.L.
    B.5.2Functional name of contact pointPivotal Medical Department
    B.5.3 Address:
    B.5.3.1Street AddressGobelas 19
    B.5.3.2Town/ cityMadrid
    B.5.3.3Post code28023
    B.5.3.4CountrySpain
    B.5.4Telephone number+34917081250
    B.5.5Fax number+34917081301
    B.5.6E-mailvanesa.pons@pivotal.es
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameIRX-2
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNINN not yet proposed see D.3.9.3
    D.3.9.2Current sponsor codeIRX-2
    D.3.9.3Other descriptive namePrimary Cytokine Components: IL-2, IL-1β, IFN-γ and TNF-α.
    D.3.10 Strength
    D.3.10.1Concentration unit Other
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number115
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCyclophosphamide
    D.3.4Pharmaceutical form Powder for solution for injection/infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCYCLOPHOSPHAMIDE
    D.3.9.1CAS number 50-18-0
    D.3.9.4EV Substance CodeSUB06859MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typerange
    D.3.10.3Concentration number500 to 1000
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameIndometacin
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNIndometacin
    D.3.9.3Other descriptive nameINDOMETACIN
    D.3.9.4EV Substance CodeSUB08180MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameOmeprazole
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNOmeprazole
    D.3.9.3Other descriptive nameOMEPRAZOLE
    D.3.9.4EV Substance CodeSUB09439MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 5
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Forceval
    D.2.1.1.2Name of the Marketing Authorisation holderAlliance Pharmaceuticals Ltd.
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameZinc-containing multivitamins
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNzinc sulphate
    D.3.9.1CAS number 7733-02-0
    D.3.9.4EV Substance CodeSUB12619MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typerange
    D.3.10.3Concentration number15 to 30
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNMultivitamins and minerals
    D.3.9.3Other descriptive nameMultivitamins and minerals
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 6
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCyclophosphamide
    D.3.4Pharmaceutical form Powder for solution for injection/infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCYCLOPHOSPHAMIDE
    D.3.9.1CAS number 50-18-0
    D.3.9.4EV Substance CodeSUB06859MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typerange
    D.3.10.3Concentration number500 to 1000
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 7
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameIndometacin
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNIndometacin
    D.3.9.3Other descriptive nameINDOMETACIN
    D.3.9.4EV Substance CodeSUB08180MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 8
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameOmeprazole
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNOmeprazole
    D.3.9.3Other descriptive nameOMEPRAZOLE
    D.3.9.4EV Substance CodeSUB09439MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 9
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Forceval
    D.2.1.1.2Name of the Marketing Authorisation holderAlliance Pharmaceuticals Ltd.
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameZinc-containing multivitamins
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNzinc sulpahate
    D.3.9.1CAS number 7733-02-0
    D.3.9.3Other descriptive nameZINC
    D.3.9.4EV Substance CodeSUB12619MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typerange
    D.3.10.3Concentration number15 to 30
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNMultivitamins and minerals
    D.3.9.3Other descriptive nameMultivitamins
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Newly Diagnosed Stage II, III or IVA Squamous Cell Carcinoma of the Oral Cavity.
    Pacientes con diagnóstico reciente de carcinoma de
    células escamosas de la cavidad oral, estadio II, III o IVA
    E.1.1.1Medical condition in easily understood language
    You have recently been found to have advanced cancer in your oral cavity, called squamous cell cancer of the oral cavity.
    Haber sido recientemente diagnosticado de cancer avanzado en su cavidad oral, llamado carcinoma de células escamosas de la cavidad oral.
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.0
    E.1.2Level PT
    E.1.2Classification code 10041857
    E.1.2Term Squamous cell carcinoma of the oral cavity
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective is to determine if the event-free survival (EFS) of subjects treated with Regimen 1 (IRX-2 Regimen with cyclophosphamide, indomethacin, zinc, omeprazole and IRX-2)
    is longer than for subjects treated with Regimen 2 (Regimen 1 with cyclophosphamide, indomethacin, zinc, omeprazole but without IRX-2).
    Key exploratory objectives for the detection of biological activity, prognostic and predictive factors, and clinical-pathologic-immunologic correlates, are included and defined in the protocol. The key exploratory endpoints will be analysed separately from, and not affect the primary endpoint analysis.
    El objetivo principal es determinar si la supervivencia sin acontecimientos (SSA) de los sujetos tratados con el Régimen 1 (Régimen IRX-2 con ciclofosfamida, indometracina, zinc, omeoprazole y IRX-2) es más prolongada que la de los sujetos
    tratados con el Régimen 2. (Régimen 1 con ciclofosfamida, indometracina, zinc, omeoprazole y sin IRX-2).
    Los objetivos exploratorios clave para detectar la actividad biológica, los factores pronosticos y predictivos y las asociaciones clínicopatológico-inmunológicas estan incluidas y definidas en el protocolo. Las variables principales exploratorias clave se analizarán por separado y no afectarán al analisis de la variable principal.
    E.2.2Secondary objectives of the trial
    Secondary objectives are:
    1. to determine if OS of subjects treated with Regimen 1 is longer than for subjects treated with Regimen 2;
    2. to compare the safety of each Regimen;
    3. to compare the feasibility of each Booster Regimen.
    Los objetivos secundarios son:
    1. Determinar si la SG de los sujetos tratados con el Régimen 1 es más prolongada que la de los sujetos tratados con el Régimen 2.
    2. Comparar la seguridad de cada régimen.
    3. Comparar la viabilidad de cada régimen de refuerzo.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Pathologically confirmed diagnosis of Stage II, III or IVA squamous cell cancer of the oral cavity (excluding the lip).
    2. Subjects: males or females at least 18 years of age at study entry.
    3. Disease is surgically resectable with a curative intent.
    4. Karnofsky Performance Status ≥ 70%.
    5. Haematological, Hepatic and Renal functions are adequate for surgical intervention.
    6. Females of child-bearing potential must have negative urine/serum pregnancy test and agree to used a highly effective form of birth control.
    7. Subjects are able to give Informed Consent and adhere to the protocol treatment plan.
    1. Confirmación por anatomía patológica del diagnostico de carcinoma de células escamosas de la cavidad oral estadio clínico II, III o IVA (excepto labio).
    2. Hombres o mujeres de al menos 18 años de edad al entrar al estudio.
    3. Enfermedad resecable mediante cirugía con intención curativa.
    4. Estado funcional de Karnofsky
    ≥70%.
    5. Función hematológica: Funciones hepaticas y renales adecuadas para la cirugía.
    6. Las mujeres potencialmente fértiles deben poder y estar dispuestas a utilizar un método anticonceptivo muy eficaz para el control de la natalidad.
    7. Estar dispuesto y ser capaz de otorgar el consentimiento informado y de
    cumplir el tratamiento del protocolo
    E.4Principal exclusion criteria
    1. Prior surgery, radiation or chemotherapy (excluding biopsy or any procedure required for supportive care).
    2. Tumour of the oropharynx.
    3. Tumour involvement likely to be associated with T4b cancer.
    4. Distant metastased (M1 disease).
    5. Diagnosis of another invasive cancer which is currently not in remission and has required treatment within the last 5 years.
    6. Known infection with hepatitis B, C or HIV.
    7. Use of any Investigational agent within 30 days of randomization.
    8. Symptomatic cardiopulmonary disease which are not clinical stable.
    9. Myocardial infarction within the last 3 months.
    10. Stroke or other cerebral vascular insufficiency within last 3 months.
    11. Daily use systemic immunosuppressive therapy or corticosteroids (except for hormone deficiency) 30 days prior to randomization.
    12. Known allergies to ciprofloxacin(or other quinolones) acetylsalicylic acid or indomethacin.
    1. Cirugía, radioterapia o quimioterapia previas (excluyendo biopsias o un
    procedimientos de urgencia necesarios para el tratamiento sintomático).
    2. Tumor orofaríngeo.
    3. Tumor probablemente relacionado con el carcinoma T4b.
    4. Metástasis a distancia (enfermedad M1).
    5. Diagnóstico previo de un cáncer invasor del cual la persona NO se ha curado y que ha precisado tratamiento en los últimos 5 años.
    6. Infección conocida por los virus de la hepatitis B o la hepatitis C o el VIH.
    7. Uso de cualquier fármaco en investigación en los 30 días anteriores a la aleatorización.
    8. Enfermedades cardiopulmonares sintomáticas inestables.
    9. Infarto de miocardio en los últimos 3 meses.
    10. Accidente cerebrovascular u otros síntomas de insuficiencia cerebrovascular
    en los últimos 3 meses.
    11. Administración diaria de tratamiento inmunosupresor o corticoesteroideo
    sistémico (excepto dosis fisiológicas por deficiencia hormonal) durante
    los 30 días anteriores.
    12. Alergia al ciprofloxacino (o a otras quinolonas) al ácido acetilsalicílico o a
    la indometacina.
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoint is event-free survival (EFS).
    Progression prior to surgical resection will not be considered an Event, but failure to resect tumor that was apparent at randomization for any reason or the presence of gross residual disease at surgery will be considered an Event. Progression after resection should be confirmed by biopsy, but in the absence of biopsy confirmation, unequivocal clinical evidence of progression in the primary or nodal sites or distant metastatic disease using RECIST v1.1 criteria will be accepted as progression. Scans (CT, MRI or PET) should be performed to restage disease and establish patterns of relapse. The date of progression will be the date on which the decision not to resect tumor that was apparent at randomization is made or the date upon which the Investigator first observes recurrent locoregional or metastatic disease by physical or radiologic examination. Death for any cause will also be considered an Event. Diagnosis of a second malignancy will not be considered an Event, but date of diagnosis, site and histology will be collected.
    El objetivo principal es la supervivencia sin acontecimientos (SSA).
    La progresión antes de la resección quirúrgica no se considerará como acontecimiento, pero no extirpar un
    tumor que se apreciaba en la aleatorización por alguna causa o o la presencia de enfermedad residual bruta en la cirugía si será considerado como acontecimiento. La progresión después de la resección deberá
    confirmarse mediante biopsia, en ausencia de confirmación mediante biopsia se aceptará como evidencia clínica inequívoca de la de la progresión en los sitios primarios o nodales el uso de criterios aceptados como progression en RECIST V1.1.
    Los escaneos (TAC, RM o PET) deberán ser realizados para se debe realizar para escenografiar la
    enfermedad y establecer patrones de recaída.
    La
    fecha de la progresión será la fecha en la que se tome la decisión de no extirpar
    un tumor que era apreciable en la aleatorización o en la que el investigador observe por primera vez, mediante exploración física o radiológica, una recidiva locorregional o enfermedad metastásica.
    La muerte por cualquier causa también
    se considerará como acontecimiento. El diagnóstico de una segunda neoplasia maligna no se considerará como acontecimiento, aunque se recogerá la fecha del diagnóstico, la localización y el tipo histológico.
    E.5.1.1Timepoint(s) of evaluation of this end point
    EFS will be assessed by physical examination at routine follow-up visits every 3 months after surgery for the first two years and every 6 months during years 3 and 4 and by chest CT scans performed yearly x 4 years.
    La SSA se evaluará mediante exploración física en las visitas de control habituales efectuadas cada 3 meses después de la cirugía durante los dos primeros años, y luego cada 6 meses durante los años 3 y 4, y mediante TAC torácica realizada con carácter anual durante 4 años.
    E.5.2Secondary end point(s)
    The secondary endpoints are overall survival (OS) and safety and feasibility.
    Survival data will be collected in all subjects (phone contact after progression will be sufficient). When the subject comes to clinic and/or is contacted by phone, the date of that contact is to be reported as an update of the subject’s survival.
    Safety of each Regimen and feasibility of the Booster Regimens will be assessed by the incidence and severity of AEs, SAEs, and subject discontinuations.
    Los objetivos secundarios son la supervivencia global (SG), seguridad y viabilidad.
    Se recogerán datos de supervivencia de todos los sujetos contacto telefónico después de la progresión). Cuando el paciente vaya al hospital o se le contacte por teléfono, se añadirá esa fecha como actualización de la supervivencia del sujeto.
    La seguridad de cada régimen y la viabilidad de los regimenes de refuerzo será evaluada según la incidencia y severidad de los acontecimientos adversos (AE), acontecimientos adversos serios e inesperados (SAEs) y la discontinuidad de los pacientes.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Survival data will be collected at each study visit after surgery at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, and 48 months with telephone calls for survival status to occur every 3 months if subject is not seen in follow-up until data collection ceases.
    All subjects will be assessed for AEs as detailed in the study schedule. AEs will be measured from day of randomisation until 30 days post-surgery and subsequently from the first day of each booster Regimen until 30 days after the completion. SAEs will be measured from day of randomization until the subject ends the trial.
    Los datos de supervivencia se recogerán en cada visita del estudio después de la cirugía, a los 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 y 48 meses mediante llamadas telefónicas para verificar el estado de supervivencia cada 3 meses si el paciente no es visto en seguimientos medico hasta que finalice la recolección de datos. Se evaluaran los acontencimientos adversos de todos los sujetos acorde al calendario del estudio. Los acontecimientos se medirá desde el día de la aleatorización hasta los 30 días después de la cirugía y posteriormente desde el primer dia de cada regimen de refuerzo hasta 30 días después de su finalización. Los acontencimientos adversos graves e inesperados (SAEs) SAEs se medirá n desde el día de la aleatorización hasta que el sujeto finaliza el ensayo
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Key exploratory objectives:
    - changes in tumor size from baseline to surgery;
    - lymphocyte infiltrates in the pre-treatment tumor biopsy, the surgical specimen and changes between these two samples.
    Additional exploratory objectives:
    - surgical pathology;
    - prognostic and predictive factors and clinical-pathologic-immunologic correlates;
    - Human papilloma virus (HPV) status;
    - the peripheral T cell receptor profile;
    - RNA expression profiling of immune-inflammatory markers.
    Objetivos exploratorios clave:
    - cambios tamaño tumor desde el inicio a la cirugía;
    - infiltrados linfocitarios en biopsia tumoral anterior a tratamiento y
    en muestra quirúrgica y variaciones entre estas.
    Objetivos exploratorios adicionales:
    - Patología quirúrgica
    - Factores con valor pronóstico y predictivo y asociaciones clínicopatológico-inmunológicas.
    -Situación virus papiloma (VPH).
    -Perfil de receptores de linfocitos T periféricos.
    -Perfiles ARN de marcadores inmunoinflamatorios
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    El regimen con tratamiento comparador tiene los mismos componentes excepto IRX-2.
    The comparator treatment regimen, has the same components except for IRX-2.
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA23
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Brazil
    Canada
    Germany
    Italy
    Spain
    Switzerland
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years6
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years6
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 100
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 100
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state30
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 96
    F.4.2.2In the whole clinical trial 200
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Post trial treatment of all subjects will follow the standard of care for each region. Subjects will also be followed for EFS every 3 months for the first 2 years and then every 6 months during years 3 to 5 post surgery. Any treatments the subject receives after completing the trial during the follow-up will be recorded.
    No se han previsto mas acciones de seguimiento que las de practica clínica habitual una vez el paciente haya finalizado.
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-10-27
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-09-30
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 05:08:58 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA